Pinealon: the Khavinson EDR tripeptide and the evidence behind it.

Pinealon is a three-amino-acid peptide, Glu-Asp-Arg or EDR, from the Khavinson lab in Saint Petersburg, sold as a neuroprotective "peptide bioregulator." The biology is interesting. We read 3 PubMed-indexed papers from 2020–2026, and that's the thinnest human evidence base of any peptide in this library.

What is Pinealon?

Pinealon is a synthetic peptide made of 3 amino acids: glutamic acid, aspartic acid, and arginine. Chemists abbreviate the sequence as EDR using single-letter codes. Molecular weight is roughly 418 g/mol.

Three residues is about as short as a peptide gets and still counts as one. There are no chemical modifications and no linkers.

That simple chemistry keeps synthesis cheap. Third-party tested reference compound pricing has been reported under $80 per 10 mg vial, so a low price here tells you nothing about quality.

The molecule came out of Vladimir Khavinson's lab at the Saint Petersburg Institute of Bioregulation and Gerontology, founded in 1992. The lab's research thread on short peptides as "gene-expression regulators" goes back to the 1970s.

Pinealon sits in a family of Khavinson peptides that includes Epitalon, Vilon, Cortagen and Livagen. All short, all synthetic, all from the same group. Pinealon's pitch to you is neuroprotection: cognitive support and modulation of Alzheimer's-relevant pathways.

How is it supposed to work?

The most thorough modern statement of Pinealon's proposed mechanism is the Khavinson group's 2020 review in Molecules, from Khavinson and colleagues. Two claims sit at the center of it.

1. EDR binds DNA-packaging proteins directly

The central claim: EDR sticks to histones or RNA inside the cell nucleus and changes which genes get expressed. No cell-surface receptor. No nuclear receptor. It's the same model the group proposes for Epitalon.

That's the piece outside scientists are most skeptical of. It's hard to picture how a 3-amino-acid peptide could specifically engage chromatin and produce predictable, sequence-specific transcription changes. No outside lab has shown it does.

2. Downstream signaling effects

The Khavinson team reports that EDR boosts the antioxidant enzymes SOD2 and GPX1 in cerebellar neurons. It also lowers two pro-death signals, caspase-3 and p53, and adjusts the MAPK/ERK cascade that controls cell survival.

They report changes in serotonin levels too, plus dendritic-spine preservation in mouse models of Alzheimer's and Huntington's.

Each individual effect is plausible. Here's the question no one has answered: does a tripeptide with no obvious DNA-binding motif really produce all of them? The alternative is that these are non-specific cellular stress responses that wouldn't reproduce in an independently designed study.

Khavinson-school peptides

Tripeptide EDR / Glu-Asp-Arg Khavinson lineage

Pinealon is on our research-content roadmap; we don’t currently stock it. The closest stocked peptide from the same Khavinson Saint Petersburg research program is Epitalon (AEDG tetrapeptide) — same lineage, same short-peptide-bioregulator concept, with a broader Western mechanistic evidence base.

Browse the catalog

What does the research actually show?

We searched PubMed for Pinealon across the 2020–2026 window and found 3 papers. One is the Khavinson group's own mechanism review.

One is a food-science paper on a related but different peptide. The third is a passing mention in a Khavinson-affiliated overview. You will find zero Western randomized controlled trials.

Khavinson 2020 mechanism review. Published in Molecules, this paper lays out the MAPK/ERK story, the antioxidant story and the Alzheimer's signaling story.

It's the most important single paper on Pinealon. It's also from the lab making the original claims, which is exactly what makes the single-source pattern so striking.

Jiang 2021 antioxidant paper. A Chinese food-science group studied a four-residue peptide called DREL, or Asp-Arg-Glu-Leu, which carries EDR as its core. They showed antioxidant activity in vivo through the Nrf2/Keap1 pathway, per Jiang and colleagues.

DREL isn't Pinealon. It has an extra amino acid and a different arrangement. It's still the closest thing to independent, non-Khavinson evidence that EDR-containing short peptides have real antioxidant biology.

What's missing from the literature. No Western randomized trials of Pinealon for any indication. No independent test of the direct-histone-binding model. No human pharmacokinetic data showing how it's absorbed or how long it lasts. No long-term safety data.

What about side effects?

There is no published human safety surveillance on Pinealon specifically. The Khavinson clinical-practice literature references mild tolerability observations, but no systematic safety data exist for this compound.

• Observations in Khavinson clinical tradition: mild injection-site reactions have been noted. Transient headache was mentioned in some early-course observations.
• Less frequently noted: changes in sleep patterns and mild GI discomfort have appeared in anecdotal reports.
• Uncharacterized theoretical concerns: chronic exposure to a peptide proposed to bind DNA-packaging proteins raises unresolved autoimmune and genotoxicity questions. Drug interactions have not been studied.

Khavinson-school peptides

third-party tested ≥99% pure Lyophilized

Three-residue Pinealon (EDR) isn’t in our catalog today; our nearest stocked Khavinson-school peptide is Epitalon (AEDG), with the same Saint Petersburg lineage and slightly broader Western mechanism work. Each lot ships with a third-party CoA documenting identity and purity.

Learn more

Is it legal? Is it FDA-approved?

Pinealon is not FDA-approved for any indication. It is not approved by the EMA either. It has Russian preclinical research history through the Khavinson program, but it doesn't appear to hold a formal therapeutic registration even in Russia.

In the United States, that leaves you with three things.

• Sale as a research compound is legal when the product is labeled for laboratory use only.
• Sale as a therapeutic is not legal. Marketing Pinealon for "cognition" or "neuroprotection" claims in humans would draw FDA enforcement action.
• There is no FDA-recognized indication, so Pinealon doesn't participate in any therapeutic standard of care.

The DEA does not schedule Pinealon. It is not a controlled substance.

What about sports and WADA?

Pinealon is not explicitly listed on the WADA Prohibited List for 2026. That doesn't make it safe to use if you're a tested athlete.

WADA's S0 category is a catch-all for any substance that has not received therapeutic approval but is being used for a performance purpose. As a non-approved peptide, Pinealon could fall under that umbrella for competing athletes.

The detection-window question is also unanswered. No published method specific to detecting EDR in urine or blood appears in the WADA-accredited literature. Any non-approved peptide should be treated as a compliance risk regardless of explicit list status.

Frequently asked questions

What is Pinealon, exactly?

A synthetic three-amino-acid peptide, Glu-Asp-Arg, abbreviated EDR, developed at the Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. It came out of the same short-peptide program that produced Epitalon, and it's marketed for cognitive support. Research-stage, and not FDA- or EMA-approved.

Is Pinealon FDA-approved?

No. The FDA, EMA, and other Western regulators haven't approved it. It has Russian preclinical history through the Khavinson program. No jurisdiction approves it as a therapeutic. In the U.S. it's sold legally only as a research reference compound.

How does Pinealon work?

The Khavinson group proposes that it binds histones, the DNA-packaging proteins, or RNA directly, and switches gene expression from there.

Downstream, that supposedly moves MAPK/ERK signaling, the antioxidant enzymes SOD2 and GPX1, the pro-death signals caspase-3 and p53, and the metabolic transcription factors PPARA and PPARG.

It's the same model the group proposes for Epitalon. No outside lab has confirmed the histone-binding step.

How is Pinealon different from Epithalon?

Both are short peptides from the same Khavinson lab. Epitalon is 4 residues, AEDG, positioned as a longevity peptide with proposed telomerase activation.

Pinealon is 3 residues, EDR, positioned for cognitive function. Epitalon has the slightly broader Western evidence base, including a 2025 telomerase replication from Brunel University. Pinealon has 3 PubMed papers in 2020–2026.

Is the Russian research credible?

The Khavinson group has published on short peptides since the 1970s, and the cell-biology work is methodically reported. It still isn't Western RCT-grade evidence, and independent replication is essentially absent.

Older Russian-language clinical reports aren't PubMed-indexed, so you can't quality-review them. The biology is plausible rather than fictional. The evidence behind it is far narrower than consumer marketing suggests.

What human evidence exists?

None of Western RCT grade. The Khavinson 2020 review describes behavior-test improvements in rodents and "memory improvement in elderly patients" from older Russian clinical practice. That older clinical material isn't PubMed-indexed and isn't accessible for independent quality review.

How much does Pinealon cost?

Third-party tested reference compound pricing in 2026 has been reported at $35–$80 per 10 mg vial across suppliers.

Given how thin the Western evidence base is, identity transparency matters more than usual here. Ask for a mass-spectrometry CoA from an accredited laboratory before you buy from anyone.